Clinical study of ZM-H1505R in HBV-infected patients
Latest Information Update: 06 May 2020
Price :
$35 *
At a glance
- Drugs Canocapavir (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Zhimeng Biopharma
- 06 May 2020 New trial record
- 05 Mar 2020 According to a Zhimeng Biopharma media release, this study will be conducted later this year.